RGNX
REGENXBIO Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +3.1% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 76 | 0 | 31.71M | $379.43M | +8 | −8 |
| Q1 2026 | 78 | -5 | 30.64M | $255.01M | +3 | −8 |
| Q4 2025 | 83 | +2 | 30.25M | $435.60M | +2 | — |
| Q3 2025 | 14 | -1 | 26.58M | $256.50M | — | −1 |
| Q2 2025 | 12 | 0 | 15.85M | $130.14M | — | — |
| Q1 2025 | 9 | -3 | 5.03M | $35.96M | +1 | −4 |
| Q4 2024 | 12 | +4 | 6.91M | $53.43M | +4 | — |
| Q3 2024 | 7 | -3 | 1.79M | $18.80M | — | −3 |
| Q2 2024 | 10 | — | 2.06M | $24.11M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 6.76M | — | $55.49M | 0.0% | n/c | 1 | SEC ↗ ×11 |
| 2 | The Vanguard Group ✦ (passive) | 3.42M | — | $28.09M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 3 | State Street Global Advisors ✦ (passive) | 1.84M | +72.9% | $15.14M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.13M | +1.9% | $9.27M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | AQR Capital Management ✦ | 930.20K | +49.9% | $7.64M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 6 | Renaissance Technologies ✦ | 735.20K | +147.7% | $6.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 291.87K | -71.6% | $2.40M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Marshall Wace ✦ | 222.34K | -1.4% | $1.83M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 207.95K | -36.4% | $1.71M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 171.52K | — | $1.41M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 111.95K | -66.4% | $919,101 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 27.98K | +6.8% | $230,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 177 holders, 39.19M shares, $343.14M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 53.41K sh @ 9.36 · $499,676
Director · 49.20K sh @ 9.14 · $449,706
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology